AR096424A1 - Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona - Google Patents
Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-onaInfo
- Publication number
- AR096424A1 AR096424A1 ARP140102072A ARP140102072A AR096424A1 AR 096424 A1 AR096424 A1 AR 096424A1 AR P140102072 A ARP140102072 A AR P140102072A AR P140102072 A ARP140102072 A AR P140102072A AR 096424 A1 AR096424 A1 AR 096424A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihidro
- ona
- compounds
- isoindol
- isoquinolin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula (1) en la que R¹, R², R³ y R⁴ se seleccionan independientemente entre H, alquilo y cicloalquilo; R⁵, R⁷ y R⁹ se seleccionan independientemente entre H y alquilo; R⁸ y R¹¹ en conjunto forman -CH₂-CH₂-; R¹⁰ es H o R¹⁰ y R¹¹ en conjunto forman -(CH₂)ʷ-; o R⁶ y R⁹ en conjunto forman -CH₂-, R⁸ es H y R¹⁰ y R¹¹ en conjunto forman -CH₂-; A es -C(O)- o -S(O)₂-; R¹² es alquilo; R¹³ es halógeno o ciano; R¹⁴ es H, alquilo o cicloalquilo; R¹⁵ es H, alquilo, cicloalquilo o halógeno; m, n y p se seleccionan independientemente entre cero y 1; w es 1, 2 ó 3; y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013076281 | 2013-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096424A1 true AR096424A1 (es) | 2015-12-30 |
Family
ID=50884887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102072A AR096424A1 (es) | 2013-05-27 | 2014-05-26 | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9695151B2 (es) |
| EP (1) | EP3004077B1 (es) |
| JP (2) | JP6416229B2 (es) |
| KR (1) | KR102436885B1 (es) |
| CN (1) | CN105143204B (es) |
| AR (1) | AR096424A1 (es) |
| BR (1) | BR112015028871B1 (es) |
| CA (1) | CA2903180C (es) |
| DK (1) | DK3004077T3 (es) |
| ES (1) | ES2763338T3 (es) |
| HK (1) | HK1213564A1 (es) |
| HR (1) | HRP20192275T1 (es) |
| HU (1) | HUE046773T2 (es) |
| LT (1) | LT3004077T (es) |
| MX (1) | MX370389B (es) |
| PL (1) | PL3004077T3 (es) |
| PT (1) | PT3004077T (es) |
| RS (1) | RS59739B1 (es) |
| RU (1) | RU2695524C2 (es) |
| SI (1) | SI3004077T1 (es) |
| TW (1) | TWI651317B (es) |
| WO (1) | WO2014191338A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6416229B2 (ja) * | 2013-05-27 | 2018-10-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新しい３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
| EP3054957B1 (en) | 2013-10-07 | 2019-10-02 | Antares Pharma, Inc. | Hematocrit modulation through needle assisted jet injection of testosterone |
| ES2850198T3 (es) * | 2014-10-08 | 2021-08-26 | Hoffmann La Roche | Derivados de espirodiamina como inhibidores de la aldosterona sintasa |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| RU2717310C1 (ru) * | 2019-06-04 | 2020-03-20 | Общество с ограниченной ответственностью "Таргет Медикалс" | Ингибиторы альдостеронсинтазы на основе производных 2-амино-4H-пиран-3-карбонитрила |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4710507A (en) * | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
| CN85100796A (zh) * | 1985-04-01 | 1986-10-01 | 辉瑞公司 | 喹啉酮衍生物的制备方法 |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| EP2627648A1 (en) * | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| JP5883501B2 (ja) * | 2011-04-26 | 2016-03-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | アルドステロンシンターゼインヒビター |
| KR101785143B1 (ko) * | 2011-09-15 | 2017-10-12 | 에프. 호프만-라 로슈 아게 | 다이하이드로퀴놀린-2-온 유도체 |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| RS59663B1 (sr) * | 2013-05-27 | 2020-01-31 | Hoffmann La Roche | Nova jedinjenja 3,4-dihidro-2h-izokinolin-1-on i 2,3-dihidro-izoindol-1-on |
| JP6416229B2 (ja) * | 2013-05-27 | 2018-10-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新しい３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
-
2014
- 2014-05-26 JP JP2016515759A patent/JP6416229B2/ja active Active
- 2014-05-26 PT PT147281315T patent/PT3004077T/pt unknown
- 2014-05-26 AR ARP140102072A patent/AR096424A1/es active IP Right Grant
- 2014-05-26 KR KR1020157033719A patent/KR102436885B1/ko active IP Right Grant
- 2014-05-26 LT LTEP14728131.5T patent/LT3004077T/lt unknown
- 2014-05-26 RU RU2015150287A patent/RU2695524C2/ru active
- 2014-05-26 SI SI201431437T patent/SI3004077T1/sl unknown
- 2014-05-26 TW TW103118318A patent/TWI651317B/zh active
- 2014-05-26 RS RS20191657A patent/RS59739B1/sr unknown
- 2014-05-26 PL PL14728131T patent/PL3004077T3/pl unknown
- 2014-05-26 WO PCT/EP2014/060790 patent/WO2014191338A1/en active Application Filing
- 2014-05-26 HU HUE14728131A patent/HUE046773T2/hu unknown
- 2014-05-26 CA CA2903180A patent/CA2903180C/en active Active
- 2014-05-26 EP EP14728131.5A patent/EP3004077B1/en active Active
- 2014-05-26 MX MX2015015010A patent/MX370389B/es active IP Right Grant
- 2014-05-26 DK DK14728131.5T patent/DK3004077T3/da active
- 2014-05-26 CN CN201480023886.XA patent/CN105143204B/zh active Active
- 2014-05-26 ES ES14728131T patent/ES2763338T3/es active Active
- 2014-05-26 BR BR112015028871-5A patent/BR112015028871B1/pt active IP Right Grant
-
2015
- 2015-11-20 US US14/947,760 patent/US9695151B2/en active Active
-
2016
- 2016-02-11 HK HK16101513.8A patent/HK1213564A1/zh unknown
-
2018
- 2018-10-03 JP JP2018188242A patent/JP6670906B2/ja active Active
-
2019
- 2019-12-17 HR HRP20192275TT patent/HRP20192275T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3004077T3 (pl) | 2020-04-30 |
| ES2763338T3 (es) | 2020-05-28 |
| KR102436885B1 (ko) | 2022-08-26 |
| RU2695524C2 (ru) | 2019-07-23 |
| HUE046773T2 (hu) | 2020-03-30 |
| DK3004077T3 (da) | 2020-01-13 |
| MX2015015010A (es) | 2016-03-09 |
| CA2903180A1 (en) | 2014-12-04 |
| JP2019023212A (ja) | 2019-02-14 |
| JP6416229B2 (ja) | 2018-10-31 |
| EP3004077B1 (en) | 2019-10-30 |
| US20160075687A1 (en) | 2016-03-17 |
| PT3004077T (pt) | 2019-12-19 |
| WO2014191338A1 (en) | 2014-12-04 |
| CN105143204A (zh) | 2015-12-09 |
| MX370389B (es) | 2019-12-11 |
| JP2016520601A (ja) | 2016-07-14 |
| JP6670906B2 (ja) | 2020-03-25 |
| BR112015028871B1 (pt) | 2022-02-01 |
| TW201533037A (zh) | 2015-09-01 |
| LT3004077T (lt) | 2020-01-27 |
| US9695151B2 (en) | 2017-07-04 |
| CA2903180C (en) | 2022-03-15 |
| CN105143204B (zh) | 2018-02-02 |
| HRP20192275T1 (hr) | 2020-03-06 |
| SI3004077T1 (sl) | 2020-01-31 |
| BR112015028871A2 (pt) | 2017-07-25 |
| RU2015150287A (ru) | 2017-06-28 |
| TWI651317B (zh) | 2019-02-21 |
| RS59739B1 (sr) | 2020-02-28 |
| EP3004077A1 (en) | 2016-04-13 |
| HK1213564A1 (zh) | 2016-07-08 |
| KR20160012145A (ko) | 2016-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099824A1 (es) | Compuestos bicíclicos | |
| AR103182A1 (es) | Inmunomoduladores | |
| AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR096424A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR104461A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas | |
| AR091416A1 (es) | Diazaespirocicloalcanos y azaespirocicloalcanos como inhibidores de atx y de lpa | |
| AR095781A1 (es) | Inhibidores de proteínas de quinasa | |
| AR092959A1 (es) | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR098048A1 (es) | Inhibidores de fgfr4 | |
| AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR093468A1 (es) | Derivados de piridina | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |